How To Trade Biotech Stocks: Can These Three Tips Help You Make More Profits?
Marc Lichtenfeld, an expert in biotech and income stocks, notes that a lot of Wall Street money moves into companies that issue positive Phase 2 clinical trial data.
YENOM NOTICIAS
Qué está moviendo el mercado.
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
10 Blue Chip Dividend Stocks Hedge Funds Are Buying
In this article, we presented the 10 blue-chip dividend stocks hedge funds are buying. Click to skip ahead and see 5 Blue Chip Dividend Stocks Hedge Funds are Buying. 2020 was one of the worst years for dividend and dividend growth stocks…
10 Blue Chip Dividend Stocks Hedge Funds Are Buying
In this article, we presented the 10 blue-chip dividend stocks hedge funds are buying. Click to skip ahead and see 5 Blue Chip Dividend Stocks Hedge Funds are Buying. 2020 was one of the worst years for dividend and dividend growth stocks…
Dow Jones Lower On Biden's $2 Trillion Stimulus Plan; U.S. Retail Sales Disappoint
The Dow Jones Industrial Average traded modestly lower in today's stock market but the major indexes did come off their lows of the day.
Dow Jones Turns Lower On Sen. Manchin Comment While Nasdaq Leads, Hits New High
The Dow Jones Industrial Average traded slightly lower in today's stock market after the major indexes all hit fresh record highs the day prior.
Dow Jones Turns Lower On Sen. Manchin Comment While Nasdaq Leads, Hits New High
The Dow Jones Industrial Average traded slightly lower in today's stock market after the major indexes all hit fresh record highs the day prior.
These 6 Dividend Payers Look Primed for Growth in Earnings—and Payouts
To find some solid income prospects for 2021, Barron’s looked for nice-yielding stocks that are expected to show good earnings growth for 2020. The results: T. Rowe Price, Best Buy, United Parcel Service, Clorox, and Amgen.
Kinnate Biopharma Stock Doubles As IPO Begins Trading
Kinnate Biopharma is a preclinical biotech focused on the discovery and development of small molecule kinase inhibitors for difficult-to-treat cancers. The IPO raised $240 million.
Kinnate Biopharma Stock Doubles As IPO Begins Trading
Kinnate Biopharma is a preclinical biotech focused on the discovery and development of small molecule kinase inhibitors for difficult-to-treat cancers. The IPO raised $240 million.
World's Leading Life Science Companies Now Enrolling COMMUNITY, A Global, Platform Trial For Hospitalized Patients With COVID-19
- A range of therapeutics will be evaluated for their potential efficacy and safety relative to the condition severity of patients hospitalized with COVID-19 - Trial sites are being established in hospitals around the world to support enro…
World's Leading Life Science Companies Now Enrolling COMMUNITY, A Global, Platform Trial For Hospitalized Patients With COVID-19
- A range of therapeutics will be evaluated for their potential efficacy and safety relative to the condition severity of patients hospitalized with COVID-19 - Trial sites are being established in hospitals around the world to support enro…